Despite outcry over cost, breakthrough drug becomes treatment of choice for hepatitis C

July 29, 2014 7:18 AM

1 0

WASHINGTON – A $1,000-per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than 3 million Americans.

According to new research, prescriptions for Sovaldi have eclipsed all other hepatitis C pills combined in less than six months.

Read more

To category page